Global Metabolic Partnering Deal Trends, Players and Financials Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Metabolic Partnering 2014-2021: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.

Global Metabolic Partnering 2014 to 2021 provides the full collection of Metabolic disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.

• Trends in Metabolic partnering deals
• Financial deal terms for headline, upfront and royalty by stage of development
• Metabolic partnering agreement structure
• Metabolic partnering contract documents
• Top Metabolic deals by value
• Most active Metabolic dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.

The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Report scope

Global Metabolic Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Metabolic trends and structure of deals entered into by leading companies worldwide.

Global Metabolic Partnering 2014 to 2021 includes:

• Trends in Metabolic dealmaking in the biopharma industry since 2014
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of Metabolic deal contract documents
• Comprehensive access to over 1100 Metabolic deal records
• The leading Metabolic deals by value since 2014
• Most active Metabolic dealmakers since 2014

Global Metabolic Partnering 2014 to 2021 provides the reader with the following key benefits:

• In-depth understanding of Metabolic deal trends since 2014
• Access Metabolic deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between Metabolic partner companies
• Comprehensive access to over 1100 links to actual Metabolic deals entered into by the world’s biopharma companies
• In-depth review of Metabolic deals entered into by the top 25 most active dealmakers
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner Metabolic opportunities
• Uncover companies actively partnering Metabolic opportunities

The initial chapters of this report provide an orientation of Metabolic dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Metabolic dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Metabolic deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Metabolic dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Metabolic deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2014. The chapter is organized by specific Metabolic therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Metabolic partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Metabolic technologies and products.

Companies Mentioned

• 2XU
• 3SBio
• 5LINX
• 23andMe
• A*STAR Agency for Science
• Technology and Research
• AB-Biotics
• Abbott Laboratories
• Abbvie
• Abby Grace Foundation
• Abeona Therapeutics
• Abiogen Pharma
• Academic Drug Discovery Consortium
• Academy Medical
• Acasti Pharma
• Accord Healthcare
• Acerus
• Aceto Corporation
• Acon Labs
• Actavis (name changed to Allergan)
• Activhealth
• Acurian
• Admera Health
• Adocia
• Advance Pharmaceutical
• Adverum Biotechnologies
• Aelan Cell Technologies
• Aero Pump
• AEterna Zentaris
• Aetna
• Aevi Genomic Medicine
• Afimmune
• AgaMatrix
• AgBiome
• Agilent Technologies
• Aguettant
• Ajinomoto
• Akero Therapeutics
• Akers Biosciences
• AKSA Medical
• Akston Biosciences
• Albany Molecular Research
• Albert Einstein College of Medicine
• Albion
• Albumedix
• Alcon Laboratories
• Alcresta
• Alexion Pharmaceuticals
• ALK-Abello
• Allegro Ophthalmics
• Allele Biotechnology and Pharmaceuticals
• Allergan
• AllerGenis
• Alliance Pharma
• All Star Health Brands
• Alnylam Pharmaceuticals
• And Many More Companies!

For more information about this report visit https://www.researchandmarkets.com/r/2rd3l3

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900